The Netherlands
Neogene Therapeutics is a clinical-stage biotechnology company founded in 2018, dedicated to innovating next-generation engineered T cell receptor therapies aimed at treating a broad array of solid cancers. The company's slogan, "Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers," underscores its mission to revolutionize cancer treatment.
With its headquarters in The Netherlands and offices in both Santa Monica, CA and Amsterdam, Neogene is strategically positioned on the global stage. As part of the AstraZeneca Group, it has access to vast resources and support, allowing it to target substantial advancements within the Biotechnology and Health Care industries.
Significant investor confidence was evident with its last investment—a $320.00M acquisition by AstraZeneca on 01 November 2022. This acquisition not only reflects the strong potential of Neogene's technologies but also establishes a robust foundation for future growth and innovation.
